Real-World Evidence Increasingly Shapes Biologic Formulary ⁢decisions

Updated June 28,2025

Payers are increasingly relying ⁣on real-world evidence (RWE) to make ⁢informed decisions about⁣ biologic formulary ⁢placement,impacting patient access and healthcare costs. This shift addresses knowlege gaps left by randomized trials, offering insights into⁢ how biologics perform in routine clinical settings.

A survey revealed that‍ 85% of ⁣U.S. payers use real-world evidence in⁣ oncology formulary decisions, notably when head-to-head trials are lacking. The⁢ most common sources of real-world data include ⁣administrative claims (79%),clinical/EHR ⁤data (69%),prospective ​observational cohorts (60%),and disease registries (37%).

Regulators and payers are ⁢embracing real-world evidence to accelerate access to innovative therapies, even ‍with initial uncertainties. Some health technology⁣ assessment‍ agencies now offer conditional formulary approval for high-cost biologics, pending further real-world outcomes data.

Advances in ‍data analytics enable rapid-cycle analyses of clinical databases, providing⁣ actionable results in‌ weeks. One health system partnered ⁣with an analytics firm to⁣ assess an analgesic’s real-world effect on surgical recovery,⁤ using millions of patient cases. This sped up formulary reviews and reduced clinician effort.

Real-world evidence case studies demonstrate its‍ impact on formulary policy. Anthem,‌ for example, analyzed claims outcomes for an oral asthma biologic versus standard inhalers. ​the real-world evidence showed fewer hospital visits ​and lower costs for patients on the oral drug who were nonadherent to inhalers. This‍ led Anthem to maintain the oral agent on a preferred tier and remove prior authorization requirements.

Pharmacy benefit managers (PBMs) may require real-world ‌data on gene therapy durability and safety before broad formulary‍ coverage, given high upfront costs and limited long-term trial data. By⁤ analyzing initial patient outcomes, ⁣PBMs can target coverage to subpopulations most likely to benefit and expand access as real-world evidence confirms value.

A claims-based study of glucagon-like peptide-1 (GLP-1) agonists for obesity found only 15% of patients remained on therapy after two years,compared ⁤to 85% adherence in clinical ‌trials. This data allows payers to adjust budget ​forecasts and revisit patient ⁢support programs ⁢to improve persistence.

Methodological considerations are ‌crucial when⁣ using real-world evidence. data validity is paramount, requiring large, representative, accurate, and complete datasets. Observational comparisons ⁢are prone to biases, necessitating mitigation strategies like⁤ propensity score matching ⁢to balance ⁢patient characteristics. ​Statistical methods, such as multivariable regression and survival analysis, strengthen causal inferences.

The integration of real-world evidence offers benefits to all stakeholders. Payers gain predictability in budgeting and can justify coverage decisions with outcomes data. Manufacturers can demonstrate a drug’s real-world value sooner, accelerating formulary inclusion. patients gain more equitable​ access to biologics, as⁢ real-world evidence encompasses diverse populations often underrepresented in trials.

the use​ of high-quality real-world evidence is accelerating and refining decision-making for biologics, aligning formulary tiering, prior authorization,⁣ and step therapy protocols with real-world value.

What’s next

the continued integration of real-world evidence into formulary decisions​ will likely lead to more personalized and cost-effective healthcare, with a greater emphasis on patient outcomes ‍and ‌value-based contracts.